Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence
about
Glutamatergic transmission in drug reward: implications for drug addictionDesign and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.Targeting glutamate homeostasis for potential treatment of nicotine dependence.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsInvolvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.Molecular Mechanism of Action of Antimalarial Benzoisothiazolones: Species-Selective Inhibitors of the Plasmodium spp. MEP Pathway enzyme, IspDmGluR2 positive allosteric modulators: a patent review (2009 - present).From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats.Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.Inhibition of c-di-GMP phosphodiesterase RocR and swarming motility by a benzoisothiazolinone derivative
P2860
Q28112161-F687AA42-5EAD-4E66-A313-2812CA7E01D8Q30414307-604A2102-FFF2-4367-B620-668FE4D70C5AQ34502468-BEB0FD48-1E84-426F-967A-DF2B6F96B11EQ36042479-3C39C7F0-85EB-4559-8EF2-38B03F5C4CFFQ37183072-2C9813C5-F1BF-4DE9-880D-D41AFACB82CCQ37315470-50B665AA-A4E3-4046-A822-08491C940D7DQ37421946-B2EFB625-AD09-4306-85A2-3EAC7FBAFCACQ38085707-CEE2F876-8E39-42CE-80AB-F0717B44AD3EQ39044068-41B319B4-1480-4BEC-AAF6-25796494B7B8Q46700405-BDBF63E4-220F-4EBD-8D7F-A4CC625B7686Q46771818-61A9BBFB-D4D3-406B-AE87-666FCDB82DFBQ47663907-AB8E46CB-EE97-4F39-A52E-0CC27DEF24F4Q47987383-B9488C87-82E0-4756-AEEE-41CCD72028E2Q57664377-00C9A3B9-C45F-4F9D-BB91-D7F6EE3B9749
P2860
Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Orally active metabotropic glu ...... t model of nicotine dependence
@ast
Orally active metabotropic glu ...... t model of nicotine dependence
@en
type
label
Orally active metabotropic glu ...... t model of nicotine dependence
@ast
Orally active metabotropic glu ...... t model of nicotine dependence
@en
prefLabel
Orally active metabotropic glu ...... t model of nicotine dependence
@ast
Orally active metabotropic glu ...... t model of nicotine dependence
@en
P2093
P2860
P356
P1476
Orally active metabotropic glu ...... t model of nicotine dependence
@en
P2093
Arianna Mangravita-Novo
Athina Markou
Douglas J Sheffler
Hilary Highfield Nickols
Layton H Smith
Manoranjan S D'Souza
Nicholas D P Cosford
Raveendra-Panickar Dhanya
Russell Dahl
P2860
P304
P356
10.1021/JM3005306
P407
P577
2012-10-23T00:00:00Z